Nanotechnology and tumor microcirculation

Advanced Drug Delivery Reviews

Volumn 74, Issue , 2014, Pages 2-11

  Kano, Mitsunobu R ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Capillary; Leakiness; Nanomedicine; Nanoparticle; Nanotechnology; Pathology; Pericyte; Permeability; Vasculature

Indexed keywords

BLOOD VESSELS; DRUG DELIVERY; MECHANICAL PERMEABILITY; MEDICAL NANOTECHNOLOGY; MICROCIRCULATION; NANOPARTICLES; NANOTECHNOLOGY; PATHOLOGY; SYNTHESIS (CHEMICAL);

ANTI-TUMOR CHEMOTHERAPEUTIC; CAPILLARY; CAPILLARY STRUCTURES; CLINICAL APPLICATION; LEAKINESS; NONAUTONOMOUS; PERICYTE; VASCULATURE;

TUMORS;

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; DEXTRAN; DOXORUBICIN; LY 364947; NANOPARTICLE; PLATINUM COMPLEX; SORAFENIB; UNCLASSIFIED DRUG; LIPOSOME; NANOCARRIER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA INHIBITOR; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CAPILLARY; COLON CANCER; DRUG EFFECT; HUMAN; MEMBRANE PERMEABILITY; MICELLE; MICROCIRCULATION; MOLECULAR WEIGHT; MULTIPLE MYELOMA; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PERICYTE; PRIORITY JOURNAL; PROSTATE TUMOR; REVIEW; TISSUE DISTRIBUTION; TUMOR VASCULARIZATION; ANIMAL; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULARIZATION; BLOOD VESSEL PERMEABILITY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG EXTRAVASATION; LIPOSOMAL DELIVERY; NANOPHARMACEUTICS; TUMOR LOCALIZATION; TUMOR MICROCIRCULATION;

ANIMALS; CAPILLARIES; HUMANS; MICROCIRCULATION; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS;

EID: 84906043943     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.08.010     Document Type: Review

References (55)

1. Chen K.G., Sikic B.I. Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin. Cancer Res. 2012, 18:1863-1869.
2. Mehlen P., Puisieux A. Metastasis: a question of life or death. Nat. Rev. Cancer 2006, 6:449-458.
3. Nguyen D.X., Bos P.D., Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 2009, 9:274-284.
4. Sugihara E., Saya H. Complexity of cancer stem cells. Int. J. Cancer 2013, 132:1249-1259.
5. Saunders N.A., Simpson F., Thompson E.W., Hill M.M., Endo-Munoz L., Leggatt G., et al. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol. Med. 2012, 4:675-684.
6. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
7. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
8. Folkman J., Merler E., Abernathy C., Williams G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 1971, 133:275-288.
9. Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146:873-887.
10. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
11. Richard D.E., Berra E., Pouysségur J. Angiogenesis: how a tumor adapts to hypoxia. Biochem. Biophys. Res. Commun. 1999, 266:718-722.
12. Dachs G.U., Tozer G.M. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur. J. Cancer 2000, 36:1649-1660.
13. Dvorak H.F., Nagy J.A., Dvorak J.T., Dvorak A.M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 1988, 133:95-109.
14. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69(Suppl. 3):4-10.
15. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
16. Rosen L.S. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002, 9:36-44.
17. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
18. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
19. Hwa C., Aird W.C. The history of the capillary wall: doctors, discoveries, and debates. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H2667-H2679.
20. Malpighi M., Borelli G.A. De pulmonibus, observationes anatomicae 1661, Typis Io. Baptistae Ferronij, Bononiae.
21. Schwann T. Microscopical Researches into the Accordance in the Structure and Growth of Animals and Plants 1847, Syndenham Society, London.
22. Vesalius A. De Humani Corporis Fabrica 1543, Johannes Oporinus, Basel, Switzerland.
23. Harvey W. Exercitatio de motu cordis et sanguinis in animalibus 1628, Guilielmi Fitzeri, Frankfurt.
24. Working P.K., Newman M.S., Huang S.K., Mayhew E., Vaage J., Lasic D.D. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth® liposomes (Doxil®). J. Liposome Res. 1994, 4:667-687.
25. Doxil Prescribing Information, 2012.
26. Dreher M.R., Liu W., Michelich C.R., Dewhirst M.W., Yuan F., Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst. 2006, 98:335-344.
27. Kano M.R., Komuta Y., Iwata C., Oka M., Shirai Y., Morishita Y., et al. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci. 2009, 100:173-180.
28. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
29. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011, 63:136-151.
30. Zimmermann K.W. Der feinere Bau der Blutcapillaren. Z. f. d. Ges. Anat. 1923, 63:29-109.
31. Leveen P., Pekny M., Gebre-Medhin S., Swolin B., Larsson E., Betsholtz C. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev. 1994, 8:1875-1887.
32. Hellstrom M., Kal n M., Lindahl P., Abramsson A., Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999, 126:3047-3055.
33. Lindblom P., Gerhardt H., Liebner S., Abramsson A., Enge M., Hellstrom M., et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev. 2003, 17:1835-1840.
34. Armulik A., Genové G., Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell 2011, 21:193-215.
35. Kano M.R., Morishita Y., Iwata C., Iwasaka S., Watabe T., Ouchi Y., et al. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J. Cell Sci. 2005, 118:3759-3768.
36. Zhang L., Nishihara H., Kano M.R. Pericyte-coverage of human tumor vasculature and nanoparticle permeability. Biol. Pharm. Bull. 2012, 35:761-766.
37. Cao Y., Zhang Z.-L., Zhou M., Elson P., Rini B., Aydin H., et al. Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer 2013, 119:313-324.
38. Weinberg R.A. The Biology of Cancer 2007, Garland Science, New York, NY, USA.
39. Kano M.R., Bae Y., Iwata C., Morishita Y., Yashiro M., Oka M., et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3460-3465.
40. Yingling J.M., Blanchard K.L., Sawyer J.S. Development of TGF-beta signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. 2004, 3:1011-1022.
41. Bae Y., Nishiyama N., Fukushima S., Koyama H., Yasuhiro M., Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug. Chem. 2004, 16:122-130.
42. Minowa T., Kawano K., Kuribayashi H., Shiraishi K., Sugino T., Hattori Y., et al. Increase in tumour permeability following TGF-beta type I receptor-inhibitor treatment observed by dynamic contrast-enhanced MRI. Br. J. Cancer 2009, 101:1884-1890.
43. Kumagai M., Kano M.R., Morishita Y., Ota M., Imai Y., Nishiyama N., et al. Enhanced magnetic resonance imaging of experimental pancreatic tumor in vivo by block copolymer-coated magnetite nanoparticles with TGF-beta inhibitor. J. Control. Release 2009, 140:306-311.
44. Miyata K., Oba M., Kano M.R., Fukushima S., Vachutinsky Y., Han M., et al. Polyplex micelles from triblock copolymers composed of tandemly aligned segments with biocompatible, endosomal escaping, and DNA-condensing functions for systemic gene delivery to pancreatic tumor tissue. Pharm. Res. 2008, 25:2924-2936.
45. Mancuso M.R., Davis R., Norberg S.M., O'Brien S., Sennino B., Nakahara T., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 2006, 116:2610-2621.
46. Cabral H., Matsumoto Y., Mizuno K., Chen Q., Murakami M., Kimura M., et al. Accumulation of sub-100nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 2011, 6:815-823.
47. Harada M., Iwata C., Saito H., Ishii K., Hayashi T., Yashiro M., et al. NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo. Int. J. Nanomedicine 2012, 7:2713-2727.
48. Yasunaga M., Manabe S., Tarin D., Matsumura Y. Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue. Bioconjug. Chem. 2011, 22:1776-1783.
49. Yasunaga M., Manabe S., Tarin D., Matsumura Y. Tailored immunoconjugate therapy depending on a quantity of tumor stroma. Cancer Sci. 2013, 104:231-237.
50. Cheng Z., Al Zaki A., Hui J.Z., Muzykantov V.R., Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 2012, 338:903-910.
51. Fröhlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int. J. Nanomedicine 2012, 7:5577-5591.
52. Chithrani B.D., Ghazani A.A., Chan W.C.W. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 2006, 6:662-668.
53. Adriani G., de Tullio M.D., Ferrari M., Hussain F., Pascazio G., Liu X., et al. The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials 2012, 33:5504-5513.
54. Yang K., Ma Y.-Q. Computer simulation of the translocation of nanoparticles with different shapes across a lipid bilayer. Nat. Nanotechnol. 2010, 5:579-583.
55. Huang C., Butler P.J., Tong S., Muddana H.S., Bao G., Zhang S. Substrate stiffness regulates cellular uptake of nanoparticles. Nano Lett. 2013, 13:1611-1615.